Who is sponsoring NCT04699838?

NCT04699838 is sponsored by Muhammad Furqan.

What condition does NCT04699838 study?

NCT04699838 studies Extensive Stage Small Cell Lung Cancer.

What drugs are being tested in NCT04699838?

Interventions: Cisplatin, Carboplatin, Etoposide, Durvalumab, Ceralasertib.

What is the status of NCT04699838?

NCT04699838 is currently RECRUITING.

Last reviewed 2025-12-30 · How we verify

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363

NCT04699838 Phase 2 RECRUITING

The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.

Details

Lead sponsor	Muhammad Furqan
Phase	Phase 2
Status	RECRUITING
Enrolment	30
Start date	2021-04-20
Completion	2026-11

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

Cisplatin
Carboplatin
Etoposide
Durvalumab
Ceralasertib

Primary outcomes

Progression Free Survival (PFS) — From enrollment until the time of disease progression, assessed for a maximum of 24 months
Progression free survival (PFS) is defined as the time from the initiation of treatment (C1D1) to the time when the criteria for disease progression is met as defined by RECIST v1.1 OR death due to any cause. The PFS is subject to right censoring due to loss to follow-up or at the end of study duration.

Countries

United States